Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3487]

Scientists uncover why some patients with rare leukaemia may not benefit from approved targeted therapy

Scientists uncover why some patients with rare leukaemia may not benefit from approved targeted therapy

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

B-cell lymphoma: Cause of high-risk disease discovered

B-cell lymphoma: Cause of high-risk disease discovered

Mass producing engineered T cells for cancer therapy using Platinum TALEN

Mass producing engineered T cells for cancer therapy using Platinum TALEN

Unearthing new cancer treatments from fungi

Unearthing new cancer treatments from fungi

CAR T cell therapy targets key mutation driving rare blood cancers

CAR T cell therapy targets key mutation driving rare blood cancers

Scientists uncover 'mix and match' mechanism for creating new cancer-fighting drugs

Scientists uncover 'mix and match' mechanism for creating new cancer-fighting drugs

Study reveals how leukaemia cells enter and damage lungs

Study reveals how leukaemia cells enter and damage lungs

$EHA 2026: Fixed-duration triplet therapy demonstrates efficacy for patients with relapsed/refractory CLL$

EHA 2026: Fixed-duration triplet therapy demonstrates efficacy for patients with relapsed/refractory CLL

$EHA 2026: Talquetamab-tgvs plus daratumumab and hyaluronidase-fihj data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

EHA 2026: Talquetamab-tgvs plus daratumumab and hyaluronidase-fihj data demonstrate the strength of a bispecific...

More from ecancer